In order to validate the value of AIF1 as a candidate biomarker of response to immunotherapy, we analyzed RNA-Seq data from the IMvigor210 study—a trial investigating responses to atezolizumab immunotherapy in patients with metastatic BLCA. The gene discussed is AIF1; the disease is bladder transitional cell carcinoma.